Taysha Gene Therapies (TSHA)

Healthcare · Biotechnology
$4.49 +1.35% on the day Market cap $1.1B 52-week range $3.69 to $7.30 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Taysha Gene Therapies's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from TSHA's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation2
Profitability0
Growth0
Financial health8
Cash efficiency0

Results from SEC filings

Fiscal years, from Taysha Gene Therapies's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue—$3M$15M$8M$10M
Net income-$175M-$166M-$112M-$89M-$109M
Free cash flow-$132M-$109M-$77M-$82M-$94M
EPS (diluted)-$4.64-$3.78-$0.96-$0.36-$0.34
Operating margin—-6492.7%-468.8%-1097.6%-1130.6%

Superinvestors who own TSHA

From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Tom Steyer
Farallon Capital Management LLC
New position $15M0.07%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $876,8830.0%Q2 2026

Insider buying

Open-market purchases by Taysha Gene Therapies's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of TSHA in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when TSHA trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Taysha Gene Therapies insiders buying the stock?

No open-market insider purchases of TSHA in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Taysha Gene Therapies?

2 of the superinvestors Investingly tracks hold TSHA in their latest 13F, including Tom Steyer, Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.